- May 22, 2019
Reata’s drug, Bardoxolone, shows promising results for chronic kidney disease
Reata is in its ‘final pivotal study’ for its new drug, bardoxolone. In the trials, the drug has showed promising results to reverse kidney damage. Yahoo Finance sits down with the CEO of Reata, Warren Huff, who founded the company in 2002, to discuss the plans to launch the product in the near future.
- May 21, 2019
Deep, transcranial magnetic stimulation for OCD
BrainsWay’s so-called depression helmet—which focuses powerful electromagnetic waves to stimulate and help rewire neurons firing deep within the brain—picked up its second clearance from the FDA last August, making it the first noninvasive device for obsessive-compulsive disorder.
- May 20, 2019
Reata’s big test approaches
Reata Pharmaceuticals has shown that perseverance can pay off. Its lead project, bardoxolone, which is now focused on rare kidney diseases, is forecast to sell $1.3bn in 2024 after earlier flopping in a broader indication. The company should soon find out whether bardoxolone is approvable, with phase III data in the project’s first indication, Alport syndrome, due in the second half of the year. And Reata and analysts alike are confident after positive results from the phase II portion of the same study.
- May 14, 2019
A booster for immuno-oncology drugs
Touting a new, more robust class of immune-oncology drugs to date, Noxopharm has released data from the first series of preclinical studies confirming that idronoxil (IDX), the active ingredient in the company’s anti-cancer drug candidate, Veyonda, not only activates, but potentially boosts the function of current immuno-oncology drugs.
- May 13, 2019
The Eye Travels Wide: ProQR’s Bid For Leadership In The Genetics Of Sight
How did a youthful vendor of IT services, faced with a personal exposure to crippling illness, attract some of the best minds in biotech to launch a company with a then-untested RNA technology that today is a contender for leadership in the rarified space of inherited retinal disease? The answer may lie in the ambitiously definitive name that 36-year-old founder Daniel de Boer gave to his enterprise with a mission: ProQR – an active synonym for finding cures.
- May 13, 2019
Bactericidal, antibiotic acne topical treatment reduces inflammatory lesions
Vyome Therapeutics reported results from two clinical trials of its anti-acne candidate VB-1953; the bactericidal, antibiotic topical gel kills sensitive and resistant strains of C.acnes infection, and has been shown to reduce inflammation, at the Society for Investigative Dermatology annual meeting in Chicago.
- May 10, 2019
All To Play For: CAR-T Specialist Celyad’s Big Year
Celyad’s leadership team talks to Scrip about the critical nature of the coming months for its lead cancer therapy product, and CAR-T market differentiation.
- May 3, 2019
NASA teams up with Israeli biotech firm to work on solving long duration spaceflight
It is one of the biggest hurdles NASA must overcome before astronauts embark on long duration space travel to Mars or building permanent settlements on the moon: how to minimize the heavy toll exacted on even the most physically fit human bodies in zero gravity. So to help ensure astronauts don’t arrive at their destination too weak to explore, the space agency has teamed up with Pluristem, an Israeli biotech company, to investigate whether injecting them with cells derived from a mother’s nutrient-rich placenta can increase muscle volume — a process now in trials on Earth for the elderly.
